A compound comprising - a biopolymer scaffold and at least - a first peptide n-mer of the general formula: P ( - S - P) (n-1) and - a second peptide n-mer of the general formula: P ( - S - P) (n-1); wherein, independently for each occurrence, P is a peptide with a sequence length of 2-13 amino acids, preferably 3-11 amino acids, more preferably 4-9 amino acids, especially 5-8 amino acids, and S is a non-peptide spacer, wherein, independently for each of the peptide n-mers, n is an integer of at least 1, preferably of at least 2, more preferably of at least 3, especially of at least 4, wherein each of the peptide n-mers is bound to the biopolymer scaffold, preferably via a linker each; wherein the biopolymer scaffold is a human protein and wherein at least one occurrence of P is a circularized peptide; wherein the compound is non-immunogenic in a human; wherein the compound is for use in intracorporeal sequestration of at least one antibody in a human individual, wherein the compound is - for use in prevention or treatment of an autoimmune disease in a human individual having the autoimmune disease or being at risk of developing the autoimmune disease or - for use in prevention or treatment of transplant rejection in a human individual having a transplant or eligible for a transplantation or - for use in prevention or treatment of adverse reactions based on anti-drug antibodies or anti-gene-delivery vector antibodies, in particular anti-AAV antibodies, in a human individual undergoing therapy with the drug or eligible for therapy with the drug or in a human individual undergoing gene therapy or eligible for gene therapy or - for use in an emergency intervention following antibody treatment or active vaccination, or - for use in transfusion medicine. - a biopolymer scaffold and at least - a first peptide n-mer of the general formula: P ( - S - P) (n-1) and - a second peptide n-mer of the general formula: P ( - S - P) (n-1); wherein, independently for each occurrence, P is a peptide with a sequence length of 2-13 amino acids, preferably 3-11 amino acids, more preferably 4-9 amino acids, especially 5-8 amino acids, and S is a non-peptide spacer, wherein, independently for each of the peptide n-mers, n is an integer of at least 1, preferably of at least 2, more preferably of at least 3, especially of at least 4, wherein each of the peptide n-mers is bound to the biopolymer scaffold, preferably via a linker each; wherein the biopolymer scaffold is a human protein and wherein at least one occurrence of P is a circularized peptide; wherein the compound is non-immunogenic in a human; wherein the compound is for use in intracorporeal sequestration of at least one antibody in a human individual, wherein the compound is - for use in prevention or treatment of an autoimmune disease in a human individual having the autoimmune disease or being at risk of developing the autoimmune disease or - for use in prevention or treatment of transplant rejection in a human individual having a transplant or eligible for a transplantation or - for use in prevention or treatment of adverse reactions based on anti-drug antibodies or anti-gene-delivery vector antibodies, in particular anti-AAV antibodies, in a human individual undergoing therapy with the drug or eligible for therapy with the drug or in a human individual undergoing gene therapy or eligible for gene therapy or - for use in an emergency intervention following antibody treatment or active vaccination, or - for use in transfusion medicine. wherein the biopolymer scaffold is a human protein and wherein at least one occurrence of P is a circularized peptide; wherein the compound is non-immunogenic in a human; wherein the compound is for use in intracorporeal sequestration of at least one antibody in a human individual, wherein the compound is - for use in prevention or treatment of an autoimmune disease in a human individual having the autoimmune disease or being at risk of developing the autoimmune disease or - for use in prevention or treatment of transplant rejection in a human individual having a transplant or eligible for a transplantation or - for use in prevention or treatment of adverse reactions based on anti-drug antibodies or anti-gene-delivery vector antibodies, in particular anti-AAV antibodies, in a human individual undergoing therapy with the drug or eligible for therapy with the drug or in a human individual undergoing gene therapy or eligible for gene therapy or - for use in an emergency intervention following antibody treatment or active vaccination, or - for use in transfusion medicine. - for use in prevention or treatment of an autoimmune disease in a human individual having the autoimmune disease or being at risk of developing the autoimmune disease or - for use in prevention or treatment of transplant rejection in a human individual having a transplant or eligible for a transplantation or - for use in prevention or treatment of adverse reactions based on anti-drug antibodies or anti-gene-delivery vector antibodies, in particular anti-AAV antibodies, in a human individual undergoing therapy with the drug or eligible for therapy with the drug or in a human individual undergoing gene therapy or eligible for gene therapy or - for use in an emergency intervention following antibody treatment or active vaccination, or - for use in transfusion medicine.